Scotland Backs Bayer's Xofigo In Prostate Cancer Before England
This article was originally published in Scrip
The Scottish Medicines Consortium (SMC) has published advice accepting six new medicines for use in NHS Scotland, three of which have yet to receive final vetting from NICE – the HTA body for England and Wales.
You may also be interested in...
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.